INTRODUCTION
============

Carbapenems are one of the last remaining antimicrobial treatments for multidrug-resistant *Enterobacteriaceae*, and resistance to this class of antibiotics is becoming a threat worldwide ([@b1-cln_67p1427]). Impermeability due to porin loss concomitant with the hyperproduction of cephalosporinases is often the cause of carbapenem resistance, but serine beta-lactamases, such as *Klebsiella pneumoniae* carbapenemase (KPC), are spreading fast and becoming prevalent worldwide ([@b1-cln_67p1427]-[@b3-cln_67p1427]). The genes encoding the KPC enzyme are usually flanked by transposon-related sequences that have been identified on transferable plasmids, giving these genes the potential to disseminate to other genera and species ([@b4-cln_67p1427]). Currently, KPC producers are found all over the world, with reports from Greece ([@b5-cln_67p1427]), Israel ([@b6-cln_67p1427]), France ([@b7-cln_67p1427]), China ([@b8-cln_67p1427]), and South America ([@b4-cln_67p1427]).

In Brazil, KPC was first described in the northwestern region in 2006 and has become an important mechanism of resistance to carbapenems since then ([@b9-cln_67p1427]-[@b11-cln_67p1427]). In our institution, carbapenem resistance among *Enterobacteriaceae* was only sporadically noted prior to 2005. However, starting in 2008, KPC producers became an epidemiological challenge.

The early recognition of KPC-producing isolates has become necessary due to the clinical and epidemiological implications of the presence of KPC. The routine laboratory detection of KPC is a challenge, especially for laboratories without molecular diagnostic resources, as is common in Brazilian hospitals.

The modified Hodge test (MHT) is a phenotypic screening test for carbapenemases that is used for epidemiological purposes, and its use is currently proposed by the Clinical and Laboratory Standards Institute (CLSI) ([@b12-cln_67p1427]). The MHT is easy to perform, but divergent specificity values have been reported, and false-positive results are a concern ([@b13-cln_67p1427],[@b14-cln_67p1427]).

The aim of this study was to evaluate the performance of a new proposal for interpreting the modified Hodge test and detect the *bla*~KPC~ gene among *Enterobacteriaceae* isolates, which were collected in our 2500--bed hospital, that exhibited ertapenem MICs ≥1 µg/ml.

MATERIALS AND METHODS
=====================

From April 2009 to July 2011, a total of 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem (ENSEs), with MICs ≥1 µg/ml from any clinical specimen, were selected from among the patient cultures of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. When more than one isolate was recovered from a patient, the second isolate was only included if it was another species or the same species with a different susceptibility pattern.

Identification and antimicrobial susceptibility testing were performed using a Vitek2 system (bioMerieux Marcy-L\'ile, France) with the AST-N105 and AST-N104 cards. Categorical interpretations were performed according to CLSI M100--S21 ([@b12-cln_67p1427]). For colistin, the CLSI breakpoints for *P. aeruginosa* were the reference for categorical interpretation, and the U.S. Food and Drug Administration (FDA) breakpoints were used for tigecycline. All isolates were tested by the MHT according to the CLSI recommendations and quality control.

The results of the modified Hodge test were categorized according to the CLSI recommendations as follows: negative when there was no distortion of the inhibition zone around the ertapenem disk, positive when any distortion of the *E. coli* ATCC 25922 (strain indicator) inhibition zone was noted around the ertapenem disk, and indeterminate when the inhibition of *E. coli* ATCC 25922 growth around the streak (tested strain) was evidenced by a clear area.

All isolates with positive modified Hodge test results were classified using a new sub-classification proposed by our group: A) a result was considered a true-positive when *E. coli* ATCC 25922 touched the ertapenem disk; and B) a result was considered inconclusive when there was distortion of the *E. coli* ATCC 25922 inhibition zone around the ertapenem disk, but the bacteria did not touch the edge of the disk. See [Figure 1](#f1-cln_67p1427){ref-type="fig"} for the modified Hodge test sub-classification definition in our study.

All isolates with positive and indeterminate modified Hodge test results were submitted to molecular detection of the *bla*~KPC~ gene by PCR. Isolates with negative test results were also randomly chosen for molecular KPC testing. The primers used for PCR amplification and the reaction conditions were described previously ([@b15-cln_67p1427]). The PCR products were visualized by electrophoresis on 2% agarose gels stained with ethidium bromide and visualized with UV light.

Two samples of *bla*~KPC~ amplicons (859 bp) produced by PCR were selected and submitted to DNA sequencing with a BigDye Terminator cycle sequencing kit v3.1 (Applied Biosystems Inc., Foster City, CA) in an MJ Research PTC-200 DNA Engine thermal cycler (Bio-Rad Laboratories, Waltham, USA). The sequencing reaction products were purified by ethanol precipitation, separated, and analyzed using an ABI Prism 3100 genetic analyzer (ABI, Foster City, USA) following the manufacturer\'s protocols. The sequenced products were compared using software available at the National Center for Biotechnology Information website (<http://blast.ncbi.nlm.nih.gov>).

The antibiograms for KPC producers and non-producers were analyzed. The MIC~50~ and MIC~90~ values were calculated using Whonet version 5.4.

The sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated according to the method of Ilstrup ([@b16-cln_67p1427]).

RESULTS
=======

We analyzed 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem, of which 30% (458) were positive for *bla*~KPC~. Among the *bla*~KPC~-positive isolates, 93% were *Klebsiella pneumoniae*. The modified Hodge test results are summarized according to the species distribution and molecular detection of *bla*~KPC~ in [Table 1](#t1-cln_67p1427){ref-type="table"}. The modified Hodge test was positive in 35.5% of *Enterobacteriaceae* isolates that were not susceptible to ertapenem (540), and according to our proposed sub-classification, 71% (386) of those isolates showed true-positive results, and 29% (154) had inconclusive results. The true-positive results showed 98% agreement with the molecular KPC results, whereas the level of agreement for the inconclusive results was only 51%.

The modified Hodge test results according to the sensitivity, specificity and predictive values for KPC detection are shown in [Table 2](#t2-cln_67p1427){ref-type="table"}. The modified Hodge test had a 100% negative predictive value.

Specimens yielding KPC-producing isolates were primarily urine samples (37%), rectal swabs (17%), blood samples (10%), and catheters (10%).

The antimicrobial susceptibility profile of the KPC-producing isolates revealed high resistance rates to all cephalosporins, aztreonam (98.9%), piperacillin/tazobactam (99.3%), and fluoroquinolones (92%). Amikacin and gentamycin had susceptibility rates of 95% and 88%, respectively. Tigecycline had an 8% susceptibility rate, and colistin had an MIC~50~ of 2 mg/l and MIC~90~ of 4 mg/l. The meropenem results for KPC isolates from the automated system indicated that 50% were resistant, but the disk method indicated that 70% of isolates were resistant (data not shown). The KPC non-producing isolates also had high rates of resistance to all cephalosporins, aztreonam, piperacillin/tazobactam, and fluoroquinolones, and the detailed information is summarized in [Table 3](#t3-cln_67p1427){ref-type="table"}.

The DNA sequencing of the KPC-producing isolates confirmed that they carried the KPC-2 variant.

DISCUSSION
==========

The presence of *bla*~KPC~ deserves special attention because isolates harboring this plasmid gene are usually multidrug resistant, limiting the therapeutic options available and causing a high mortality rate ([@b17-cln_67p1427]).

KPC represents an epidemiological challenge for infection control groups because it can spread very quickly, and there are limited treatment options available ([@b18-cln_67p1427]). The early detection of such isolates is critical. Screening for KPC producers by identifying *Enterobacteriaceae* isolates that are not susceptible to ertapenem has a low specificity but is a starting point to identify isolates harboring carbapenemases. The modified Hodge test is relatively easy to perform in standard microbiology laboratories, and the standardization of the interpretation of the results may improve the specificity of this test for KPC detection.

Infections caused by KPC-producing isolates are now a concern in our institution, and 30% of the *Enterobacteriaceae* isolates that were not susceptible to ertapenem were KPC positive in this study period. The majority of those isolates (37%) were from urine cultures, but the positivity rate for KPC among blood isolates was proportionally higher (data not shown).

The molecular detection of *bla*~KPC~ is the gold standard for diagnosis, but the majority of standard laboratories in our country do not have the resources necessary to perform this test on a routine basis. Phenotypic tests should be made available to detect KPC early or rule it out. The modified Hodge test may detect the presence of carbapenemases, but it is not specific for KPC and may have false-positive results due to non-carbapenemase enzymes, such as AmpC and/or extended-spectrum beta-lactamases (ESBLs), combined with porin loss. Positive results could also be due to other carbapenemases. In the literature, the specificity of the modified Hodge test differs because some authors analyzed data for distinct bacteria groups, such as non-fermenters and *Enterobacteriaceae*, and detected different carbapenemases, such as NDM ([@b13-cln_67p1427]). In our study, the modified Hodge test was evaluated only for *Enterobacteriaceae* bacteria and KPC producers, which may explain the high level of agreement with the molecular results.

The proposed positive modified Hodge test category had 98% agreement with the molecular *bla*~KPC~ results, highlighting the good positive predictive value of KPC detection among *Enterobacteriaceae* when a standardized method for interpretation is in place. Seven isolates showed true-positive results and were negative for *bla*~KPC~, but an accurate analysis of the reason for these discrepancies was limited because no tests were performed for other carbapenemases. Of the isolates in the inconclusive group, 49% were negative for *bla*~KPC~, and these negative strains most likely produced CTX-M or hyperproduced AmpC in association with porin loss. Another possibility is that these isolates produced carbapenemases other than KPC.

The indeterminate result, as proposed by the CLSI, does not have a clear microbiological or clinical interpretation in the literature and should be the focus of future studies.

*Enterobacteriaceae* bacteria that not susceptible to ertapenem but have a negative modified Hodge test result are not KPC producers.

Although tests other than the modified Hodge test, such as the aminophenylboronic acid and dipicolinic acid tests, may also be options for the phenotypic screening for carbapenemases ([@b19-cln_67p1427]), the supplies necessary for these tests are not routinely available in the majority of Brazilian laboratories.

The antibiograms of the 458 KPC isolates generated using the automated system revealed multidrug resistance and showed that 43% of isolates were susceptible to meropenem (MIC ≤1 µg/ml). The meropenem susceptibility rates were not reproducible by TREK microdilution panels (Cleveland, OH) or the disk diffusion method (OXOID) (data not shown), with 45% very major errors (VMEs) for this drug. Corroborating these findings, the literature contains reports of unacceptable VME levels for meropenem when KPC isolates were tested using automated systems. Microbiologists and clinicians should be aware of the current problems regarding false susceptibility results for meropenem among KPC isolates when only automated systems are used to screen isolates ([@b20-cln_67p1427]). Regarding the colistin and tigecycline Vitek results, our internal validation process did not show major discrepancies with the E-test (data not shown), and published studies have not reported major problems with these drugs ([@b21-cln_67p1427]). Every laboratory should perform its own validation of automated systems when CLSI breakpoints are in place.

The modified Hodge test results for *Enterobacteriaceae* using standardized readings are a useful phenotypic and epidemiological tool to identify KPC isolates while waiting for molecular results. Negative modified Hodge test results ruled out all KPC isolates in our institution in an efficient and timely manner.
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###### 

Distribution of 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem (ENSE) according to the modified Hodge test (MHT) results and the presence of *bla*~KPC~.

  MHT results[a](#tfn1-cln_67p1427){ref-type="table-fn"})N° ENSE   Organism                                                    N° ENSE(*bla*~KPC~ tested)   *bla*~KPC~Negative   *bla*~KPC~Positive   
  ---------------------------------------------------------------- ----------------------------------------------------------- ---------------------------- -------------------- -------------------- -----------
                                                                                                                               *K. pneumoniae*              481 (191)            191                  0
                                                                                                                               *E. cloacae*                 293 (111)            111                  0
                                                                                                                               *E. aerogenes*               85 (16)              16                   0
                                                                                                                               *E. coli*                    62 (22)              22                   0
                                                                                                                               *S. marcescens*              15 (8)               8                    0
  Negative                                                                                                                     *P. mirabilis*               12 (1)               1                    0
  975 (64.1%)                                                                                                                  *M. morgannii*               8 (0)                0                    0
                                                                                                                               *C. freundii*                7 (4)                4                    0
                                                                                                                               *E. gergoviae*               7 (2)                2                    0
                                                                                                                               *K. oxytoca*                 2 (0)                0                    0
                                                                                                                               *P. stuartii*                2 (0)                0                    0
                                                                                                                               *P. vulgaris*                1 (0)                0                    0
                                                                                                                               Total                        975 (355)            355 (100%)           0 (0)
                                                                   True-positive[b](#tfn2-cln_67p1427){ref-type="table-fn"})   *K. pneumoniae*              \(354\)              1                    353
                                                                   386 (71%)                                                   *E. cloacae*                 \(10\)               3                    7
                                                                                                                               *E. aerogenes*               \(3\)                0                    3
                                                                                                                               *E. coli*                    \(6\)                0                    6
                                                                                                                               *S. marcescens*              \(6\)                3                    3
                                                                                                                               *C. koseri*                  \(1\)                0                    1
  Positive                                                                                                                     *C. freundii*                \(1\)                0                    1
  540 (35.5%)                                                                                                                  *E. asburiae*                \(2\)                0                    2
                                                                                                                               *K. oxytoca*                 \(2\)                0                    2
                                                                                                                               Total                        \(386\)              7 (2%)               379 (98%)
                                                                   Inconclusive[b](#tfn2-cln_67p1427){ref-type="table-fn"})    *K. pneumoniae*              \(111\)              40                   71
                                                                   154 (29%)                                                   *E. cloacae*                 \(26\)               24                   2
                                                                                                                               *E. aerogenes*               \(10\)               10                   0
                                                                                                                               *E. coli*                    \(2\)                0                    2
                                                                                                                               *E. gergoviae*               \(2\)                2                    0
                                                                                                                               *E. asburiae*                \(1\)                0                    1
                                                                                                                               *S. marcescens*              \(2\)                0                    2
                                                                                                                               Total                        \(154\)              76 (49%)             78 (51%)
  Indeterminate                                                                                                                *E. cloacae*                 \(4\)                3                    1
  6 (0.4%)                                                                                                                     *E. coli*                    \(1\)                1                    0
                                                                                                                               *K. pneumoniae*              \(1\)                1                    0
                                                                                                                               Total                        \(6\)                5 (86%)              1 (14%)
  Total: 1521                                                                                                                                               \(901\)              443                  458

Positive, indeterminate, and negative results were defined according to the recommendations of the Clinical and Laboratory Standards Institute.

True-positive and inconclusive results were defined according to this study\'s proposal (see [Figure 1](#f1-cln_67p1427){ref-type="fig"}).

###### 

Performance of the modified Hodge test (MHT) for KPC detection.

  MHT                                                    N° Isolates   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ------------------------------------------------------ ------------- ----------------- ----------------- --------- ---------
  True-positive                                          386           100               98                98        100
  Inconclusive                                           154           100               82                51        100
  Positive[a](#tfn3-cln_67p1427){ref-type="table-fn"})   540           100               81                85        100

True-positive plus inconclusive results.

PPV - positive predictive value, NPV -- negative predictive value.

###### 

*In vitro* activity of antimicrobial agents tested against 901 ENSE isolates.

  Antibiotic[a](#tfn5-cln_67p1427){ref-type="table-fn"})    KPC producers (458)          KPC non-producers (443)                                             
  --------------------------------------------------------- --------------------- ------ ------------------------- ----- ----- -- ------ ----- ------ ------ -----
  PTZ                                                       99.3                  0.7    0                         128   128      93.3   2.1   4.6    128    128
  Ceftazidime                                               82.9                  5.6    11.5                      64    64       91     2     7      64     64
  Cefotaxime                                                94.7                  3.7    1.5                       64    64       95.9   0.7   3.4    64     64
  Cefepime                                                  54.0                  23.5   22.5                      64    64       68.7   4.6   26.7   64     64
  Aztreonam                                                 98.9                  0.3    0.8                       64    64       93.4   0.8   5.8    64     64
  Ertapenem                                                 100                   0      0                         8     8        99.5   0.5   0      4      8
  Imipenem                                                  69.8                  16.4   13.8                      8     16       22.5   8     69.5   1      8
  Meropenem                                                 50                    7      43                        2     16       27.9   3.6   68.4   0.25   8
  Amikacin                                                  3.1                   1.5    95.4                      2     16       17     3     80     2      64
  Gentamicin                                                11                    1      88                        1     16       48.3   2.3   49.4   8      16
  Ciprofloxacin                                             92                    1      7                         4     4        79.5   2.5   18     4      4
  SUT                                                       94                    0      6                         16    16       60.4   0     39.6   16     16
  Colistin[b](#tfn6-cln_67p1427){ref-type="table-fn"})      32                    0      68                        0.5   16       11.7   0.5   87.8   0.5    16
  Tigecycline[c](#tfn7-cln_67p1427){ref-type="table-fn"})   8                     15     77                        2     4        11     13    76     1      8

Minimum inhibitory concentration (MIC) breakpoint in mg/L, as determined by the Vitek2® system.

Breakpoint for *P. aeruginosa* according to the Clinical and Laboratory Standards Institute.

U.S. Food and Drug Administration (FDA) breakpoints.

SUT: trimethoprim/sulfamethoxazole; PTZ: piperacillin/tazobactam; ENSE: *Enterobacteriaceae* not susceptible to ertapenem; KPC: *Klebsiella pneumoniae* carbapenemases; R: resistant; I: intermediate; S: susceptible.

[^1]: Cury AP designed and conducted the study, and was also responsible for the microbiological procedures, data collection, analysis and interpretation, and manuscript drafting. Andreazzi D contributed to the interpretation and presentation of the results, statistical analysis and manuscript review. Maffucci M and Caiaffa-Junior HH conducted the molecular biological procedures. Rossi F mentored Cury AP, conducted the analysis of the results and was also responsible for the manuscript writing, review and approval.
